Content Quality: Clean, well-structured News piece (690 words, within the 400-1200 range) organized into Overview / What We Know / What We Don't Know. No direct quotes are used (so no verbatim-quote risk), and no AI self-reference. Tone is neutral and matches standard science-journalism conventions.
Source Verification: Read all 4 snapshots captured by chief:review under sources/2026-07/frog-gut-bacterium-ewingella-americana-eliminates-colorectal-tumors-in-mice-with-a-single-dose-jaist-study-finds/. Verified sha256 of each decompressed .html.gz against manifest.json (all match). source-1.html.gz (ScienceDaily), source-2.html.gz (SciTechDaily), and source-3.html.gz (MedicalXpress, archive_fallback=true, Wayback capture 2026-06-27) all contain full, readable article text and corroborate the core claims: 100% CR rate with a single IV dose, outperformance vs anti-PD-L1 and liposomal doxorubicin, dual cytotoxic/immune mechanism, ~3,000-fold intratumoral bacterial increase in 24h, TNF-a/IFN-y cytokine release, ~1.2h blood half-life with clearance by 24h, zero healthy-organ colonization, transient inflammation resolving within 72h, 60-day toxicity observation window, and identical future-directions list (breast/pancreatic/melanoma, oral delivery, combination therapy). source-0.html.gz (the primary PMC paper, PMC12710904) was NOT usable for verification: despite a recorded status_code 200 in the manifest, the decompressed snapshot is a reCAPTCHA/bot-check interstitial page ('Checking your browser - reCAPTCHA... before accessing pmc.ncbi.nlm.nih.gov'), not the article content. This is a soft failure the automated fetcher did not detect (200 status but non-article body). Several specific claims in the article are sourced exclusively to this paper and are not corroborated in the three secondary write-ups: the 200 mm3 tumor-volume treatment threshold and tail-vein route, the exact anti-PD-L1 comparator result ('only one complete response'), the doxorubicin comparator result ('failed to consistently eradicate tumors'), the tumor-rechallenge experiment (10/10 cured mice resisting re-injection vs 10/10 untreated controls developing tumors), the '60 days' framing as immunological-memory duration specifically (vs. the secondary sources' use of 60 days only for toxicity observation), the 'at least 30 days' survival extension, and the 'narrow therapeutic window' / dose-fractionation / antibiotic-fail-safe discussion in What We Don't Know. Per the mandatory source-reading protocol, since the archived snapshot could not support these claims, I fell back to a live WebFetch of https://pmc.ncbi.nlm.nih.gov/articles/PMC12710904/ (last resort, as instructed for failed/unusable snapshots) and it successfully returned the real paper content this time. I cross-checked every one of the above claims against the live-fetched text and all were confirmed verbatim or near-verbatim: 'tumors reached approximately 200 mm3 in volume', 'single intravenous administrations via tail vein injection', 'only one complete response (CR) was observed in the anti-PD-L1-treated group', doxorubicin 'did not achieve consistent tumor eradication', 'all E. americana-cured mice (0/10 developed tumors)' vs 'uniform tumor growth in naive controls (10/10)', 'immunological memory persisting beyond 60 days', 'extended mouse survival by at least 30 days compared with PBS-treated controls', and a narrow-therapeutic-window / dose-fractionation / intratumoral-injection / antibiotic-fail-safe discussion matching the article's What We Don't Know section. No fabrications, no hallucinated specifics, and no misattribution were found. The 'nine strains screened for anticancer activity' claim (attributed to the paper's abstract) is also consistent with the live-fetched text ('Nine bacterial strains advanced to detailed antitumor evaluation after biocompatibility screening' out of 45 total isolated) -- the article's phrasing is a defensible paraphrase, not an error, even though the secondary write-ups frame the same fact differently (emphasizing the 45-strain starting pool).
Factual Accuracy: No hallucinated statistics, names, or quotes detected. Every specific number checked (100% CR, 3,000-fold, 1.2-hour half-life, 72-hour inflammation resolution, 60-day observation/memory window, 30-day survival extension, 200 mm3 tumor threshold, 10/10 rechallenge outcomes) traces to a cited source, either the secondary snapshots or the live-verified primary paper. Headline, summary, and lead paragraph are all directly supported by the ScienceDaily and PMC content.
Overall Assessment: High-quality, accurately sourced submission. All claims verified against source content (three secondary snapshots read directly from disk; the primary PMC paper verified via live WebFetch after its archived snapshot proved to be a bot-check page rather than the article). No fabrications, no misattributions, no orphan sources, tone neutral, category word count in range, genuinely new topic. Approved without corrections.